Sheila Jacobs is a journalist whose work has appeared in various medical publications, including Psychiatry Advisor, Pulmonology Advisor, Rheumatology Advisor, and Neurology Advisor. She covers a range of topics in the medical field, including respiratory health, genetic testing, and treatment options for various conditions.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Sheila Jacob's coverage primarily focuses on medical research, with a strong emphasis on citing data. Given this focus, she is likely to be most responsive to pitches that offer access to new and significant scientific findings in the fields of medical research and healthcare.
As her articles are heavily reliant on data, sources or experts who can provide robust scientific evidence or insights from clinical studies would likely capture her attention. Pitches offering exclusive access to researchers involved in groundbreaking studies related to Prader-Willi Syndrome, Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency, and Idiopathic Pulmonary Fibrosis may also be well-received.
While there is no specified geographic focus for Sheila's work, it’s clear that she has a broad interest in impactful medical research regardless of location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
| Some early adopting hospitals advocate ETCOc testing on every neonate, along with a 24-hour transcutaneous bilirubin or total serum
High titers of anti-A and anti-B appear to be one of the issues involved in ABO hemolytic disease of the fetus and newborn (HDFN) and hemolytic
| Among individuals with newly diagnosed pediatric idiopathic thrombocytopenia, including fetal and neonatal alloimmune thrombocytopenia (FNAIT), an
| To care for those with pulmonary arterial hypertension (PAH), it is essential to develop tools that can simplify disease diagnosis and
| The identification of red flags for immunoglobulin G4-related disease (IgG4-RD) is associated with improved referrals to centers of
| The study revealed that the 2022 criteria demonstrated high sensitivity and specificity for EGPA, low sensitivity and high specificity
| Using simpler, less time-consuming devices for administering treatment to individuals with hemophilia can help improve the quality of life
| Among patients with paroxysmal nocturnal hemoglobinuria (PNH), fluorescent aerolysin (FLAER) binding has been shown to be abnormally low
| In patients with pulmonary arterial hypertension (PAH), all models derived from the Swedish PAH & CTEPH [chronic thromboembolic pulmonary
By: Sheila Jacobs
In murine models of hemophilia A with inhibitors, busulfan/fludarabine or melphalan/ fludarabine preconditioning, followed by 2bF8 lentivirus (LV)-transduced hematopoietic stem cell transplantation (HSCT), can effectively and safely initiate sustained platelet factor VIII (FVIII) expression and generate immune tolerance, according to findings from a study published recently in the Journal of Thrombosis and Haemostasis.
(833) 317-6278 
